Our Company

Current Focus

The current focus of EPH Technologies is the commercialization of our life-changing treatments based on our proprietary serum, Enzoplex, including our Protenza serums in Mexico. We are also preparing to launch online sales of our Protenza skin repair products and our Hydrenza skin care line worldwide.

Product Development

Our Chief Technology Officer and inventor of our proprietary microbial bioreactors and serum production process, Michael Saunders, has studied the propagation benefits of microbial enzymes for over a decade. We originally formed the company to leverage his research in microbiological applications to develop products to reduce specific toxic substances and "crack" problematic hydrocarbon chains endemic to oil production. Our first product, E^{3}OR (Oil Remediation), was a biological formulation of microbes that triggered the cold hydrocracking of long-chain hydrocarbons in oil excavation and storage equipment.

A Breakthrough

While the results of the initial trials in oil wells exceeded expectations, Mr. Saunders identified a second viable market segment when he noticed grass growing in the soil of an otherwise barren oilfield hydrated with wastewater from E^{3}OR treatments. Mr. Saunders immediately began to focus on proving the observed organic benefit of the microbes and the enzymes and proteins they produced. Additional testing on soil for growing more domesticated plant life, including lawns, trees, flowers and vegetables, resulted in unusually high growth rates and a discernible increase in overall resilience during winter months. We observed yield increases to such a degree, and in such controlled circumstances, that the beneficial effect of the product was irrefutable.

Through a process of analysis, application, and observation we conjectured that if plants growing in soil treated with the microbial byproduct could more effectively resist pest attacks and recover so substantially from the effects of seasonal change, it might also be possible for *other* organisms to benefit from this health promoting product. Additionally, considering that extensive exposure to the product caused no skin irritation, adverse reaction, or side effect, any potential toxicity of the product was of less concern.

Process Optimization

In order to trigger the microbes to produce the byproduct enzymes and proteins in a laboratory setting, Mr. Saunders constructed a bio-reactor, or microbe incubator, to simulate the "down hole" atmosphere of an oil well. He subsequently developed process changes, improved ingredient quality, and refined clarification techniques in order to isolate the beneficial components of the biochemical response of the microbes when subject to various environmental stresses and stimuli. Finally, Mr. Saunders modified the filtration process to remove systemic contaminants and optimize production efficiencies. The resulting enzyme and protein rich byproduct became known as our E^{3}CP (Cellular Permeation) "serum" (which is now Enzoplex, the proprietary enzyme and protein blend in all our product lines).

Initial Application

When a friend of the company approached Mr. Saunders to inquire as to whether the E3CP serum might also affect the health of his dog plagued with cancer tumors ravaging several of its vital organs, they decided to try the product instead of the lethal injection recommended by the veterinarian. After only a few days of ingesting the serum mixed with its food, the dog appeared more energetic, mobile and interactive. All parties, however, were staggered by the news that the dog's cancer tumors had shrunk to an undetectable size within only a few weeks. It was then we came to believe the profound notion that this plant-health promoting product could have a significant effect on the immune system of *any* organism.

Clinical Trials & Approvals

After forming EPH Technologies, our founders called on contacts in the medical community in Mexico City, a hotbed for progressive research and development of new medicines and "alternative" medical treatments, to organize, within a certified clinically controlled environment, a clinical study of the efficacy of Enzoplex on humans with various ailments characterized by inflammation, including cancer, diabetes, and arthritis. We believe that the significant results from these clinical studies validate our Business Plan for the commercialization of the Protenza and Hydrenza product lines.

Our Strategy

Over the past 18 months we have funded clinical trials conducted in Mexico City by Dr. Luis Barcenas in conjunction with National Autonomous University of Mexico (Universidad Nacional Autónoma de México or UNAM). Based upon the results of these studies, Dr. Barcenas has prepared an Application for Distribution to be submitted to Comision Federal para la Proteccion contra Riesgos Sanitarios (COFEPRIS), the Mexican equivalent of the U.S. Food and Drug Administration, which will enable EPH to distribute its Protenza products throughout Mexico as a "supplement" for use in connection with the treatment of (i) arthritis, (ii) diabetes, (iii) cancer and (iv) general immune system support. Our products with be available over the counter in pharmacies and may also be recommended directly by physicians.

Our serum production methods are very scalable and can be reproduced with sufficient cultivation time to meet almost any forecast demand. We intend to manufacture and distribute a minimum of 200,000 Protenza serum units per month in just 12 months and close to one million units per month after 36 months. Even at one million units per month, our Protenza serum products would only capture a fraction (<3%) of the identified potential markets in Mexico.

We plan to launch our Protenza and Hydrenza product lines in Mexico City to leverage our access to existing distribution channels. We also believe the proximity of our current clinical trials and research studies will assist our initial marketing efforts. After completing the infrastructure construction required to distribute Protenza products in Mexico, we intend to generate additional revenue by licensing distribution rights through venture partnerships with "best of breed" companies and individuals to accomplish maximum market penetration throughout Latin America.